Journal of Shanghai Jiao Tong University (Medical Science) >

2024 , Vol. 44 >Issue 7: 847 - 858

DOI: https://doi.org/10.3969/j.issn.1674-8115.2024.07.006

Basic research

Correlation analysis of COMP and autophagy in diabetic nephropathy and its functional verification

  • Yunxin WEI ,
  • Xushun JIANG ,
  • Mengyao CAI ,
  • Ruizhi WEN ,
  • Xiaogang DU
Expand
  • Department of Nephrology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
DU Xiaogang, E-mail: cqmudxg@163.com.

Received date: 2023-12-15

  Accepted date: 2024-06-18

  Online published: 2024-07-28

Supported by

National Natural Science Foundation of China(82200799);Chongqing Natural Science Foundation General Project(cstc2019jcyj-msxmX0504)

Fold

Abstract

Objective ·To further clarify the mechanism of podocyte damage by studying the expression of cartilage oligomeric matrix protein (COMP) in glomerular podocytes and its relationship with podocyte autophagy under high glucose environment. Methods ·The gene expression dataset GSE104948 was downloaded from the GENE EXPRESSION OMNIBUS (GEO) database, and differentially expressed genes (DEGs) were obtained via GEO2R. The molecular functions and signaling pathways related to differential genes were summarized. The most correlated key genes (hub genes) were acquired by Weighted Gene Co-Expression Network Analysis (WGCNA) and the protein-protein interaction network (PPI) of DEGs was constructed with STRING database. The enrichment analysis was performed again. Conditionally immortalized mouse podocyte cells were cultured in vitro. After being fully differentiated, they were stimulated with high glucose, and the expressions of COMP, mammalian target of rapamycin (mTOR), microtubule-associated protein 1 light chain3 (LC3) and other proteins in podocytes were detected by Western blotting. The shRNA constructed by lentiviral vector was further used to infect podocytes to inhibit the expression of COMP, and the stable cell strains were screened by puromycin. The expression of COMP, mTOR, and LC3 of stable strains were detected by Western blotting, in order to observe the effect of COMP on autophagy. Results ·A total of 362 DEGs were filtered for subsequent analysis. Among these DEGs, 284 genes were up-regulated and 78 genes were down-regulated. The results of Gene Onotology (GO) term analysis showed that DEGs in diabetic nephropathy (DN) were mainly enriched in cell surface receptor signaling pathway, receptor binding, etc. The main enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways included phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/AKT) signaling pathway, extracellular matrix (ECM)-receptor interaction, etc. Sixty-four hub genes were refined through the intersection of WGCNA and PPI hub genes, and the hub genes with significantly increased or decreased expression were sifted. The hub genes were annotated with KEGG again, and it was found that most of the hub genes were enriched in "ECM-receptor interaction" and "PI3K/AKT signaling pathway". The PI3K/AKT/mTOR signaling pathway is a classic autophagy pathway, and COMP was absolutely overexpressed (logFC>2) in the 64 hub genes, suggesting that it may affect autophagy through this pathway. Western blotting showed that compared with the mannitol control group and the low glucose group, the expression of COMP in podocytes was significantly increased under high glucose stimulation. Compared with the control group, the expression of LC3-II in the high glucose group was significantly decreased, indicating that the autophagy initiation of podocytes was inhibited under the high glucose environment. Compared with the negative control, the expression of LC3-II in renal podocytes of mice with knockdown of COMP was significantly increased, and the mTOR decreased with the decrease of the expression of COMP, indicating that inhibiting COMP contributed to the recovery of autophagy in podocytes. Conclusion ·COMP is highly expressed in DN patients and highly enriched in ECM receptor and PI3K/AKT signaling pathway. Autophagy in mouse renal podocytes is inhibited under high glucose conditions, and the high expression of COMP induced by high glucose may be a key factor in autophagy inhibition. Inhibiting COMP helps to restore autophagy in mouse renal podocytes.

Key words： diabetic nephropathy; podocyte; autophagy; bioinformatics; differential gene; cartilage oligomeric matrix protein (COMP)

Cite this article

Yunxin WEI , Xushun JIANG , Mengyao CAI , Ruizhi WEN , Xiaogang DU . Correlation analysis of COMP and autophagy in diabetic nephropathy and its functional verification[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024 , 44(7) : 847 -858 . DOI: 10.3969/j.issn.1674-8115.2024.07.006

References

1 THOMAS M C, BROWNLEE M, SUSZTAK K, et al. Diabetic kidney disease[J]. Nat Rev Dis Primers, 2015, 1: 15018.
2 CAMERON J S. The discovery of diabetic nephropathy: from small print to centre stage[J]. J Nephrol, 2006, 19(Suppl 10): S75-S87.
3 ATKINS R C, ZIMMET P. Diabetic kidney disease: act now or pay later[J]. Kidney Int, 2010, 77(5): 375-377.
4 ZIYADEH F N, WOLF G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy[J]. Curr Diabetes Rev, 2008, 4(1): 39-45.
5 MIZUSHIMA N, KOMATSU M. Autophagy: renovation of cells and tissues[J]. Cell, 2011, 147(4): 728-741.
6 HE C C, KLIONSKY D J. Regulation mechanisms and signaling pathways of autophagy[J]. Annu Rev Genet, 2009, 43: 67-93.
7 KATAYAMA M, KAWAGUCHI T, BERGER M S, et al. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells[J]. Cell Death Differ, 2007, 14(3): 548-558.
8 RACANELLI A C, KIKKERS S A, CHOI A M K, et al. Autophagy and inflammation in chronic respiratory disease[J]. Autophagy, 2018, 14(2): 221-232.
9 BRAVO-SAN PEDRO J M, KROEMER G, GALLUZZI L. Autophagy and mitophagy in cardiovascular disease[J]. Circ Res, 2017, 120(11): 1812-1824.
10 DUANN P, LIANOS E A, MA J J, et al. Autophagy, innate immunity and tissue repair in acute kidney injury[J]. Int J Mol Sci, 2016, 17(5): 662.
11 CHEN W T, HUNG K C, WEN M S, et al. Impaired leukocytes autophagy in chronic kidney disease patients[J]. Cardiorenal Med, 2013, 3(4): 254-264.
12 YASUDA-YAMAHARA M, KUME S, TAGAWA A, et al. Emerging role of podocyte autophagy in the progression of diabetic nephropathy[J]. Autophagy, 2015, 11(12): 2385-2386.
13 KUME S, THOMAS M C, KOYA D. Nutrient sensing, autophagy, and diabetic nephropathy[J]. Diabetes, 2012, 61(1): 23-29.
14 JIANG X S, CHEN X M, WAN J M, et al. Autophagy protects against palmitic acid-induced apoptosis in podocytes in vitro[J]. Sci Rep, 2017, 7: 42764.
15 YU S M W, BONVENTRE J V. Acute kidney injury and progression of diabetic kidney disease[J]. Adv Chronic Kidney Dis, 2018, 25(2): 166-180.
16 LIN Q S, BANU K, NI Z H, et al. Podocyte autophagy in homeostasis and disease[J]. J Clin Med, 2021, 10(6): 1184.
17 YANG D Y, LIVINGSTON M J, LIU Z W, et al. Autophagy in diabetic kidney disease: regulation, pathological role and therapeutic potential[J]. Cell Mol Life Sci, 2018, 75(4): 669-688.
18 TAGAWA A, YASUDA M, KUME S, et al. Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy[J]. Diabetes, 2016, 65(3): 755-767.
19 JIANG X S, XIANG X Y, CHEN X M, et al. Inhibition of soluble epoxide hydrolase attenuates renal tubular mitochondrial dysfunction and ER stress by restoring autophagic flux in diabetic nephropathy[J]. Cell Death Dis, 2020, 11(5): 385.
20 LENOIR O, JASIEK M, HéNIQUE C, et al. Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis[J]. Autophagy, 2015, 11(7): 1130-1145.
21 LAPLANTE M, SABATINI D. mTOR signaling in growth control and disease[J]. Cell, 2012, 149(2): 274-293.
22 WULLSCHLEGER S, LOEWITH R, HALL M N. TOR signaling in growth and metabolism[J]. Cell, 2006, 124(3): 471-484.
23 HAY N, SONENBERG N. Upstream and downstream of mTOR[J]. Genes Dev, 2004, 18(16): 1926-1945.
24 INOKI K, MORI H, WANG J Y, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice[J]. J Clin Invest, 2011, 121(6): 2181-2196.
25 XIAO T L, GUAN X, NIE L, et al. Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice[J]. Mol Cell Biochem, 2014, 394(1): 145-154.
26 G?DEL M, HARTLEBEN B, HERBACH N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice[J]. J Clin Invest, 2011, 121(6): 2197-2209.
27 CINà D P, ONAY T, PALTOO A, et al. Inhibition of MTOR disrupts autophagic flux in podocytes[J]. J Am Soc Nephrol, 2012, 23(3): 412-420.
28 POSEY K L, COUSTRY F, HECHT J T. Cartilage oligomeric matrix protein: compopathies and beyond[J]. Matrix Biol, 2018, 71/72: 161-173.
29 LI Q, WANG C, WANG Y F, et al. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways[J]. J Exp Clin Cancer Res, 2018, 37(1): 231.
30 ASANUMA K, MUNDEL P. The role of podocytes in glomerular pathobiology[J]. Clin Exp Nephrol, 2003, 7(4): 255-259.
31 LI Y, PAN Y, CAO S R, et al. Podocyte EGFR inhibits autophagy through upregulation of Rubicon in type 2 diabetic nephropathy[J]. Diabetes, 2021, 70(2): 562-576.
32 KAWACHI H, MIYAUCHI N, SUZUKI K, et al. Role of podocyte slit diaphragm as a filtration barrier[J]. Nephrology (Carlton), 2006, 11(4): 274-281.
33 ANIL KUMAR P, WELSH G I, SALEEM M A, et al. Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus[J]. Front Endocrinol, 2014, 5: 151.
34 LIN J S, SUSZTAK K. Podocytes: the weakest link in diabetic kidney disease?[J]. Curr Diab Rep, 2016, 16(5): 45.
35 NAGATA M. Podocyte injury and its consequences[J]. Kidney Int, 2016, 89(6): 1221-1230.
36 WIGGINS J E, GOYAL M, SANDEN S K, et al. Podocyte hypertrophy, “adaptation,” and “decompensation” associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction[J]. J Am Soc Nephrol, 2005, 16(10): 2953-2966.
37 PAGTALUNAN M E, MILLER P L, JUMPING-EAGLE S, et al. Podocyte loss and progressive glomerular injury in type II diabetes[J]. J Clin Invest, 1997, 99(2): 342-348.
38 SUSZTAK K, RAFF A C, SCHIFFER M, et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy[J]. Diabetes, 2006, 55(1): 225-233.
39 YI M X, ZHANG L, LIU Y, et al. Autophagy is activated to protect against podocyte injury in adriamycin-induced nephropathy[J]. Am J Physiol Renal Physiol, 2017, 313(1): F74-F84.
40 PARZYCH K R, KLIONSKY D J. An overview of autophagy: morphology, mechanism, and regulation[J]. Antioxid Redox Signal, 2014, 20(3): 460-473.
41 QI Y Y, ZHOU X J, CHENG F J, et al. Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-α in lupus nephritis[J]. Ann Rheum Dis, 2018, 77(12): 1799-1809.
42 SUN M Y, WANG S J, LI X Q, et al. CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway[J]. Front Pharmacol, 2019, 10: 224.
43 ZHENG S T, SHEN T X, LIU Q, et al. CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway[J]. J Cell Physiol, 2021, 236(7): 5373-5386.
44 JUN W D, MAKINO H. Inflammation and the pathogenesis of diabetic nephropathy[J]. Clin Sci (Lond), 2013, 124(3): 139-152.
45 SAMSU N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment[J]. Biomed Res Int, 2021, 2021: 1497449.
46 THOMAS M C, GROOP P H, TRYGGVASON K. Towards understanding the inherited susceptibility for nephropathy in diabetes[J]. Curr Opin Nephrol Hypertens, 2012, 21(2): 195-202.
47 FREEDMAN B I, BOSTROM M, DAEIHAGH P, et al. Genetic factors in diabetic nephropathy[J]. Clin J Am Soc Nephrol, 2007, 2(6): 1306-1316.
48 VUGA L J, MILOSEVIC J, PANDIT K, et al. Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis[J]. PLoS One, 2013, 8(12): e83120.
49 MAGDALENO F, ARRIAZU E, DE GALARRETA M R, et al. Cartilage oligomeric matrix protein participates in the pathogenesis of liver fibrosis[J]. J Hepatol, 2016, 65(5): 963-971.
50 HOLDEN P, MEADOWS R S, CHAPMAN K L, et al. Cartilage oligomeric matrix protein interacts with type IX collagen, and disruptions to these interactions identify a pathogenetic mechanism in a bone dysplasia family[J]. J Biol Chem, 2001, 276(8): 6046-6055.
51 TAN K M, DUQUETTE M, JOACHIMIAK A, et al. The crystal structure of the signature domain of cartilage oligomeric matrix protein: implications for collagen, glycosaminoglycan and integrin binding[J]. FASEB J, 2009, 23(8): 2490-2501.
52 CHEN F H, HERNDON M E, PATEL N, et al. Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan[J]. J Biol Chem, 2007, 282(34): 24591-24598.
53 DI CESARE P E, CHEN F S, MOERGELIN M, et al. Matrix-matrix interaction of cartilage oligomeric matrix protein and fibronectin[J]. Matrix Biol, 2002, 21(5): 461-470.
54 FU Y, KONG W. Cartilage oligomeric matrix protein: matricellular and matricrine signaling in cardiovascular homeostasis and disease[J]. Curr Vasc Pharmacol, 2017, 15(3): 186-196.
55 WIS?OWSKA M, JAB?O?SKA B. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis[J]. Clin Rheumatol, 2005, 24(3): 278-284.
56 HUA W, HUANG H Z, TAN L T, et al. CD36 mediated fatty acid-induced podocyte apoptosis via oxidative stress[J]. PLoS One, 2015, 10(5): e0127507.
57 HUANG Y Q, XIA J H, ZHENG J G, et al. Deficiency of cartilage oligomeric matrix protein causes dilated cardiomyopathy[J]. Basic Res Cardiol, 2013, 108(5): 374.
Options
Outlines

/

〈 〉